FDA approves lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant ...
Jun 7, 2023
0
2